AEQUUS PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.01 CAD | -33.33% |
|
-33.33% | -60.00% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 12.47 | 10.05 | 13.43 | 15.25 | 4.642 | 3.316 |
| Enterprise Value (EV) 1 | 12.1 | 11.79 | 14.03 | 15 | 7.13 | 8.165 |
| P/E ratio | -4.18 x | -3.24 x | -10.7 x | -8.19 x | -1.45 x | -1.12 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 8.84 x | 6.16 x | 5.18 x | 5.62 x | 3.36 x | 13 x |
| EV / Revenue | 8.58 x | 7.22 x | 5.41 x | 5.52 x | 5.17 x | 32 x |
| EV / EBITDA | -4.59 x | -5.2 x | -20.4 x | -9.38 x | -2.77 x | -2.76 x |
| EV / FCF | -7.97 x | -13.4 x | -20.3 x | -19.6 x | -6.69 x | -6.28 x |
| FCF Yield | -12.5% | -7.47% | -4.92% | -5.1% | -14.9% | -15.9% |
| Price to Book | 7.41 x | -11.5 x | 23.4 x | 8.53 x | -3.36 x | -0.77 x |
| Nbr of stocks (in thousands) | 80,437 | 80,438 | 111,917 | 132,634 | 132,634 | 132,634 |
| Reference price 2 | 0.1550 | 0.1250 | 0.1200 | 0.1150 | 0.0350 | 0.0250 |
| Announcement Date | 4/24/19 | 4/29/20 | 4/23/21 | 6/30/22 | 5/1/23 | 4/30/24 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1.139 | 1.41 | 1.633 | 2.593 | 2.715 | 1.38 |
| EBITDA 1 | -3.815 | -2.634 | -2.266 | -0.6886 | -1.599 | -2.576 |
| EBIT 1 | -4.002 | -2.808 | -2.441 | -0.7798 | -1.608 | -2.583 |
| Operating Margin | -351.27% | -199.12% | -149.54% | -30.08% | -59.22% | -187.17% |
| Earnings before Tax (EBT) 1 | -3.882 | -2.804 | -3.106 | -1.045 | -1.81 | -3.21 |
| Net income 1 | -3.882 | -2.804 | -3.106 | -1.045 | -1.81 | -3.21 |
| Net margin | -340.74% | -198.81% | -190.26% | -40.32% | -66.66% | -232.65% |
| EPS 2 | -0.0572 | -0.0371 | -0.0386 | -0.0112 | -0.0140 | -0.0242 |
| Free Cash Flow 1 | -2.522 | -1.517 | -0.8809 | -0.691 | -0.7646 | -1.066 |
| FCF margin | -221.35% | -107.6% | -53.96% | -26.65% | -28.16% | -77.25% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/27/18 | 4/24/19 | 4/29/20 | 4/23/21 | 6/30/22 | 5/1/23 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 1.73 | 0.6 | - | 2.49 | 4.85 |
| Net Cash position 1 | 0.37 | - | - | 0.26 | - | - |
| Leverage (Debt/EBITDA) | - | -0.7646 x | -0.8782 x | - | -0.9661 x | -1.638 x |
| Free Cash Flow 1 | -1.52 | -0.88 | -0.69 | -0.76 | -1.07 | -1.3 |
| ROE (net income / shareholders' equity) | -141% | -772% | 690% | -153% | -1,570% | 105% |
| ROA (Net income/ Total Assets) | -75.2% | -83.2% | -20.3% | -26.9% | -53.5% | -133% |
| Assets 1 | 3.729 | 3.735 | 5.156 | 6.739 | 6.006 | 2.222 |
| Book Value Per Share 2 | 0.0200 | -0.0100 | 0.0100 | 0.0100 | -0.0100 | -0.0300 |
| Cash Flow per Share 2 | 0 | 0.0100 | 0.0200 | 0.0200 | 0 | 0 |
| Capex 1 | 0.01 | 0 | 0.01 | 0 | - | - |
| Capex / Sales | 0.81% | 0.16% | 0.48% | 0.15% | - | - |
| Announcement Date | 4/24/19 | 4/29/20 | 4/23/21 | 6/30/22 | 5/1/23 | 4/30/24 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -60.00% | 1.45M | |
| +33.25% | 704B | |
| +28.59% | 577B | |
| -3.55% | 348B | |
| +18.16% | 327B | |
| +4.36% | 288B | |
| +14.81% | 234B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -3.69% | 147B |
- Stock Market
- Equities
- AQS Stock
- Financials Aequus Pharmaceuticals Inc.
